RET TKI: Potential Role in Thyroid Cancers

被引：52
作者：
Antonelli, Alessandro [1 ]
Fallahi, Poupak [1 ]
Ferrari, Silvia Martina [1 ]
Mancusi, Caterina [1 ]
Colaci, Michele [2 ]
Santarpia, Libero [3 ,4 ]
Ferri, Clodoveo [2 ]
机构：
[1] Univ Pisa, Sch Med, Dept Internal Med, I-56100 Pisa, Italy
[2] Univ Modena & Reggio E, Dept Internal Med, Rheumatol Unit, I-4100 Modena, Italy
[3] Hosp Prato, Dept Oncol, Translat Res Unit, I-59100 Prato, Italy
[4] Ist Toscana Tumori, I-59100 Prato, Italy
来源：
CURRENT ONCOLOGY REPORTS | 2012年 / 14卷 / 02期
关键词：
Papillary thyroid cancer; Medullary thyroid cancer; Targeted molecular therapies; Tyrosine kinase inhibitors; RET; VEGFR; GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; TYROSINE KINASE INHIBITOR; ACTIVATED PROTEIN-KINASE; PAPILLARY CARCINOMAS; ONCOGENIC RET; MEDULLARY; VANDETANIB; SORAFENIB; EXPRESSION;
D O I：
10.1007/s11912-012-0217-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (RET/PTC) or signaling kinases (vascular endothelial growth factor receptor [VEGFR]) involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies able to inhibit RET (sorafenib, imatinib, vandetanib) in stabilizing the course of the disease. The aim of the introduction of these targeted therapies is to extend life duration assuring a good quality of life; however, further studies are needed to reach these goals.
引用
收藏
页码：97 / 104
页数：8
相关论文
共 74 条
[21]   Dysregulated RET signaling in thyroid cancer [J].
Castellone, Maria Domenica ;
Santoro, Massimo .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2008, 37 (02) :363-+
[22]   Vandetanib First Global Approval [J].
Commander, Helen ;
Whiteside, Glenn ;
Perry, Caroline .
DRUGS, 2011, 71 (10) :1355-1365
[23]  
Coxon A, 2011, J ENDOCRINOL IN 0321
[24]   RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: Evidence for molecular and functional interactions between RET and EGFR [J].
Croyle, Michelle ;
Akeno, Nagako ;
Knauf, Jeffrey A. ;
Fabbro, Doriano ;
Chen, Xu ;
Baumgartner, Jacqueline E. ;
Lane, Heidi A. ;
Fagin, James A. .
CANCER RESEARCH, 2008, 68 (11) :4183-4191
[25]   Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma [J].
Cuccuru, G ;
Lanzi, C ;
Cassinelli, G ;
Pratesi, G ;
Tortoreto, M ;
Petrangolini, G ;
Seregni, E ;
Martinetti, A ;
Laccabue, D ;
Zanchi, C ;
Zunino, F .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (13) :1006-1014
[26]   Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications [J].
Cui, Jingrong Jean .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2007, 17 (09) :1035-1045
[27]   Increasing incidence of thyroid cancer in the United States, 1973-2002 [J].
Davies, L ;
Welch, HG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (18) :2164-2167
[28]   A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma [J].
de Groot, J. W. B. ;
Zonnenberg, B. A. ;
van Ufford-Mannesse, P. Quarles ;
de Vries, M. M. ;
Links, T. P. ;
Lips, C. J. M. ;
Voest, E. E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09) :3466-3469
[29]   RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors [J].
de Groot, Jan Willem B. ;
Links, Thera P. ;
Plukker, John T. M. ;
Lips, Cornelis J. M. ;
Hofstra, Robert M. W. .
ENDOCRINE REVIEWS, 2006, 27 (05) :535-560
[30]   Mechanisms of disease:: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy [J].
Drosten, Matthias ;
Puetzer, Brigitte M. .
NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (10) :564-574
12345678